PPARG and Insulin resistance: Full PPAR-γ agonist such as pioglitazone involves an adiponectin-dependent pathway, which increases adiponectin levels, ameliorating insulin resistance, increasing AMPK activation, and decreasing gluconeogenesis in the liver [19].